These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. Giaccone G; Huizing M; Postmus PE; ten Bokkel Huinink WW; Koolen M; van Zandwijk N; Vermorken JB; Beijnen JH; Dalesio O; Pinedo HM Semin Oncol; 1995 Aug; 22(4 Suppl 9):78-82. PubMed ID: 7544030 [TBL] [Abstract][Full Text] [Related]
50. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer. Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477 [TBL] [Abstract][Full Text] [Related]
51. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer. Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033 [TBL] [Abstract][Full Text] [Related]
52. Biweekly paclitaxel and cisplatin: a phase I/II study in the first-line treatment of metastatic breast cancer. O'Reilly SE; Gelmon KA Semin Oncol; 1995 Jun; 22(3 Suppl 6):109-11. PubMed ID: 7597426 [TBL] [Abstract][Full Text] [Related]
53. Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. Klastersky J; Sculier JP Semin Oncol; 1994 Oct; 21(5 Suppl 8):39-43. PubMed ID: 7939762 [TBL] [Abstract][Full Text] [Related]
54. A phase I dose finding study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced esophageal cancer. van der Gaast A; Kok TC; Vos R; Kerkhofs L; Splinter TA Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-82-S19-85. PubMed ID: 9427273 [TBL] [Abstract][Full Text] [Related]
55. Paclitaxel plus doxorubicin in breast cancer: an Italian experience. Frassineti GL; Zoli W; Silvestro L; Serra P; Milandri C; Tienghi A; Gianni L; Gentile A; Salzano E; Amadori D Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-19-S17-25. PubMed ID: 9374087 [TBL] [Abstract][Full Text] [Related]
56. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Rowinsky EK; Jiroutek M; Bonomi P; Johnson D; Baker SD Clin Cancer Res; 1999 Apr; 5(4):767-74. PubMed ID: 10213211 [TBL] [Abstract][Full Text] [Related]
57. The activity of paclitaxel in gastrointestinal tumors. Ajani JA; Ilson DH; Kelsen DP Semin Oncol; 1995 Oct; 22(5 Suppl 12):46-50; discussion 51-3. PubMed ID: 7481861 [TBL] [Abstract][Full Text] [Related]
58. Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancer. Tolcher AW; Gelmon KA Semin Oncol; 1995 Aug; 22(4 Suppl 8):28-32. PubMed ID: 7638639 [TBL] [Abstract][Full Text] [Related]
59. Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report. Hussain M; Salwen W; Kucuk O; Ensley J Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-43-S19-45. PubMed ID: 9427265 [TBL] [Abstract][Full Text] [Related]
60. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]